MedTrace Logo

Non-invasive Prenatal Diagnostic Validation Study

NCT01574781 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1781

Last updated 2013-07-02

No results posted yet for this study

Summary

The primary purpose of this study is to collect maternal blood samples from pregnant women to develop a non-invasive prenatal diagnostic test based on fetal DNA isolated from maternal blood.

Conditions

  • Chromosome 13 Aneuploidy
  • Chromosome 18 Aneuploidy
  • Chromosome 21 Aneuploidy
  • Sex Chromosome Aberrations
  • Other Microdeletions

Interventions

PROCEDURE

Blood draw

Blood is drawn at the appropriate time given their cohort inclusion.

PROCEDURE

Cheek swab/Saliva Sampling

In lieu of blood draw, male relatives may donate cheek swab or saliva sample. Children born to participating women can donate cheek swab or saliva sample soon after birth.

Sponsors & Collaborators

  • Natera, Inc.

    lead INDUSTRY

Principal Investigators

  • Matthew Rabinowitz, PhD · Natera, Inc.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-09-30
Primary Completion
2013-04-30
Completion
2013-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01574781 on ClinicalTrials.gov